Carillion PLC
27 September 2004
Carillion's joint venture company appointed preferred provider to run its first
treatment centre valued at around £50 million
A Carillion-led joint venture, Patient Choice Partners (PCP), has been appointed
preferred bidder to design, build, finance and operate an Independent Sector
Treatment Centre (ISTC) at Basildon and Thurrock University Hospital in Essex.
In line with its strategy, Carillion is building on the established positions it
already holds in the health market by extending its service offering to include
clinical services.
PCP will provide the treatment centre and deliver three main services: an
endoscopy service, which will transfer from the existing Basildon Hospital, a
chemotherapy service being devolved from Southend and a medical day case
service, which will provide additional capacity for Basildon and Thurrock
University Hospital NHS Trust.
The unit will be staffed by around 650 full-time equivalent clinicians and
support staff.
John McDonough, chief executive of Carillion said: 'Health is an important
growth sector for Carillion and we are already an established leader in
providing PPP hospitals, ProCure 21 and facilities management services to a
number of NHS Trusts. We are delighted to have been selected as the preferred
bidder for our first ISTC and look forward to working alongside Basildon and
Thurrock University Hospital NHS Trust to provide quicker access to high quality
services for patients and the local Primary Care Trusts.'
'The ISTC programme is one of a number of important new initiatives underpinning
the Government's commitment to improving services through working with the
private sector to deliver total healthcare solutions.'
Notes to editors
PCP is a 50:50 joint venture of Carillion plc and Nestor Healthcare Group plc.
PCP's clinical partner is Medi-Clinic Ltd, a major South African private
hospital group. PCP's management team comprises a blend of extensive experience
of operating at a senior level within the NHS and the private sector.
Carillion is one of the UK's leading Support Services and Construction companies
with extensive healthcare and PFI experience. It has financially closed six PPP
hospitals, and is currently the preferred bidder for three further hospitals -
the Queen Alexandra hospital project in Portsmouth and the William Osler and
Royal Ottawa Hospitals, in Ontario, Canada - with a combined value of £1.8
billion
Nestor is the UK's leading provider of private health and care professionals as
well as services to the NHS.
Medi-Clinic currently operates 432 private hospitals in South Africa with 6,000
beds and around 12,000 employees. It treats 365,000 patients per annum of which
100,000 are treated on a day care basis.
For further information contact
John Denning, Director Group Corporate Affairs 01902 316426
Paula Manning, Group Corporate Communications Manager 01902 316444
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.